GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanisms

被引：5
|
作者：
Gomez-Peralta, Fernando [1 ]
Abreu, Cristina [1 ]
Rizzo, Manfredi [2 ]
机构：
[1] Gen Hosp Segovia, Unit Endocrinol & Nutr, Segovia, Spain
[2] Univ Palermo, Sch Med, Promise Dept, Palermo, Italy
来源：
JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2023年 / 37卷 / 08期
关键词：
GLP-1 receptor agonists; SGLT2; inhibitors; Safety; Clinical practice; Research; GLOMERULAR-FILTRATION-RATE; SEMAGLUTIDE; OUTCOMES;
D O I：
10.1016/j.jdiacomp.2023.108553
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
    Consoli, Agostino
    Formoso, Gloria
    Baldassarre, Maria Pompea Antonia
    Febo, Fabrizio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (03) : 293 - 302
  • [2] The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
    Secrest, Matthew H.
    Udell, Jacob A.
    Filion, Kristian B.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2017, 27 (03) : 194 - 202
  • [3] SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
    De Block, Christophe
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05) : 349 - 352
  • [4] GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?
    Santulli, Gaetano
    Mone, Pasquale
    Varzideh, Fahimeh
    FUTURE CARDIOLOGY, 2025, 21 (01) : 5 - 8
  • [5] Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
    Edwards, Khary
    Li, Xilong
    Lingvay, Ildiko
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (04) : 920 - 930
  • [6] Positioning of GLP-1 receptor agonists and SGLT2 inhibitors: what do the guidelines say in diabetes?
    Darmon, P.
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2023, 27 (02): : 62 - 65
  • [7] SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
    Rolek, Bartosz
    Haber, Mateusz
    Gajewska, Magdalena
    Rogula, Sylwester
    Pietrasik, Arkadiusz
    Gasecka, Aleksandra
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (08)
  • [8] Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1566): : 26 - 28
  • [9] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina
    Marsolo, Keith
    Shah, Raj C.
    Jones, W. Schuyler
    Gordon, Howard
    Hwang, Wenke
    Ayoub, Isabella
    Ford, Daniel
    Chamberlain, Alanna
    Rao, Ajaykumar
    Fonseca, Vivian
    Chang, Alexander
    Ahmad, Faraz
    Hung, Adriana
    Hunt, Kelly
    Butler, Javed
    Bosworth, Hayden B.
    Pagidipati, Neha
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 696 - 708
  • [10] The use of SGLT2 inhibitors and GLP-1 receptor agonists in older patients: a debate on approaches in CKD and non-CKD populations
    Liabeuf, Sophie
    Minutolo, Roberto
    Floege, Jurgen
    Zoccali, Carmine
    CLINICAL KIDNEY JOURNAL, 2025, 18 (02)
12345